RxDoctor Payments Data

Leo Noragbon, MD

Geriatric Psychiatry · Stockbridge, GANPI 1336324144

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 12 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 7 manufacturers reported payments, led by Johnson & Johnson at 32.4% of the total. 2025 is the largest year on record at $113, 2.2 times the $51 reported in 2021.

$250in general payments, 2019–2025

Across 12 payments — averaging $20.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$81
  • Indivior Inc.$38
  • Otsuka America Pharmaceutical, Inc.$35
  • Teva Pharmaceuticals USA, Inc.$28
  • Neurocrine Biosciences, Inc.$25
  • E.r. Squibb & Sons, L.L.C.$23
  • plus $20 from 1 others

What the payments were for

  • Food & beverage$250100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

Too few geriatric psychiatry providers in Georgiato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$523,822
Medicare patients
635
Services billed
7,779

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Risperdal ConstaRisperidone Microspheres47$53,412
Divalproex Sodium677$19,305
EliquisApixaban19$9,193
Memantine Hcl451$8,892
Venlafaxine Hcl ErVenlafaxine Hcl170$7,738
Chlorpromazine Hcl33$7,391
Mirtazapine446$6,010
Divalproex Sodium ErDivalproex Sodium110$5,426
Perphenazine122$4,999
Paliperidone ErPaliperidone95$4,855
Duloxetine Hcl265$3,337
Quetiapine Fumarate388$3,091
Oxcarbazepine118$2,867
Trazodone Hcl424$2,754
Prazosin Hcl305$2,421

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonRisperdal Consta$81$53,41247 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few geriatric psychiatry providers in Georgiaon file to place this against a meaningful peer group, so we don't.

Other geriatric psychiatry in Stockbridge

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →